Valiant Organics Q1 FY27: consol PAT triples to ₹29.3 Cr as Pharma turns profitable

Valiant Organics's consolidated PAT for Q1 FY27 (quarter ended 30 June 2026) came in at ₹29.26 Cr, up 256.8% YoY from ₹8.20 Cr and up 86.2% QoQ from ₹15.72 Cr, on revenue of ₹231.54 Cr (+13.3% YoY, +6.3% QoQ). Standalone tells a similar but less dramatic story: PAT of ₹21.82 Cr, up 187.9% YoY and 44.3% QoQ on identical revenue of ₹231.54 Cr — both bases point to a genuine operating improvement, not just a consolidation artifact, though the gap between the two (257% vs 188% YoY PAT growth) is real and traces to one large item flagged below. Basic EPS was ₹10.44 (consolidated) versus ₹2.93 a year ago and ₹5.61 last quarter. The primary driver is the Pharma segment, newly split out as a separate reportable segment this quarter (Ind AS 108, per the company's own note): standalone Pharma segment result swung from a ₹0.83 Cr loss in Q1 FY26 to a ₹8.99 Cr profit this quarter, while the base Speciality Chemicals segment grew profit 44.3% YoY to ₹25.06 Cr on 16.6% higher segment revenue. On top of this standalone-level improvement, the consolidated statement carries a ₹7.23 Cr share of profit from an indirect associate (Valiant Laboratories Limited, held via Dhanvallabh Ventures LLP) — up from just ₹0.62 Cr a year ago and ₹0.61 Cr last quarter, a roughly 12x jump that alone adds about ₹6.6 Cr to consolidated PAT beyond what standalone growth would imply; stripping that swing out, adjusted consolidated PAT growth is closer to +176% YoY, still strong but not the full +257% headline. Finance costs eased to ₹5.13 Cr from ₹6.05 Cr YoY, aiding the bridge, while employee costs rose 10.6% YoY. Net margin (PAT/total income) expanded to 12.46% from 3.99% YoY and 7.09% last quarter, consistent with the segment-level profitability shift rather than a one-line accounting item. There is no consensus estimate on record for this stock and a web search turned up no Q1 FY27 brokerage previews, so vs-street cannot be assessed; the company also carries no formal prior guidance in our records or found via search, so beat/miss/met cannot be judged either — this print stands on its own numbers. No management press release accompanied the filing (only the board-outcome letter), so there is no company framing to reconcile against the figures. Alongside the results, the board approved the re-appointment of Managing Director Sathiababu K. Kallada for a fresh three-year term (May 2027-May 2030) and a shift of the registered office to Tarapur, Boisar (Palghar), with the corporate office already relocated to Vikhroli, Mumbai — both governance/administrative items unrelated to the quarter's numbers. Separately, a proposed restructuring under which Valiant Organics would have exited Dhanvallabh Ventures LLP in exchange for a direct stake in Valiant Laboratories was called off via a cancelled postal ballot on 18 June 2026, so the associate structure behind this quarter's ₹7.23 Cr profit-share line remains unchanged going into Q2.